Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Merck
Dow
McKesson
Boehringer Ingelheim

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR HORIZANT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Horizant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01533753 ↗ Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer Terminated University of Wisconsin, Madison Phase 2 2012-02-01 The purpose of this study is to assess the change in quality of life over a 6 month period between gabapentin and venlafaxine in men with prostate cancer treated for hot flashes related to androgen deprivation therapy.
NCT01668667 ↗ Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study Completed XenoPort, Inc. Phase 4 2012-06-01 Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently approved in the United States for the treatment of adults with moderate-to-severe primary Restless Legs Syndrome (RLS). The aim of this study is to compare the efficacy, tolerability, and safety of GEn at lower doses (450 and 300 mg/day) as well as the already approved dose of 600 mg/day versus placebo for the treatment of subjects with moderate to severe primary RLS. This study is being conducted as a post-marketing commitment (PMC) as a condition of the approval of HORIZANT tablets (NDA 022399).
NCT01675960 ↗ Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children Terminated Gillette Children's Specialty Healthcare Phase 2 2012-04-01 This study is a prospective, randomized, double blind, placebo controlled, crossover clinical trial looking at whether gabapentin can provide symptom relief for chronic irritability in neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and safe for children with chronic irritability that persists despite identification and appropriate management of symptom sources.
NCT01675960 ↗ Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children Terminated Scott Schwantes, M.D. Phase 2 2012-04-01 This study is a prospective, randomized, double blind, placebo controlled, crossover clinical trial looking at whether gabapentin can provide symptom relief for chronic irritability in neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and safe for children with chronic irritability that persists despite identification and appropriate management of symptom sources.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Horizant

Condition Name

Condition Name for Horizant
Intervention Trials
Restless Legs Syndrome 3
RLS 3
Narcotic Use 1
Neurologically Impaired 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Horizant
Intervention Trials
Restless Legs Syndrome 8
Syndrome 4
Psychomotor Agitation 4
Pain, Postoperative 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Horizant

Trials by Country

Trials by Country for Horizant
Location Trials
United States 66
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Horizant
Location Trials
California 6
Florida 5
Texas 5
Tennessee 4
South Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Horizant

Clinical Trial Phase

Clinical Trial Phase for Horizant
Clinical Trial Phase Trials
Phase 4 8
Phase 3 1
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Horizant
Clinical Trial Phase Trials
Completed 4
Terminated 4
Recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Horizant

Sponsor Name

Sponsor Name for Horizant
Sponsor Trials
XenoPort, Inc. 6
Scott Schwantes, M.D. 1
University of California, Davis 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Horizant
Sponsor Trials
Other 11
Industry 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Harvard Business School
AstraZeneca
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.